All In MedTech

Device Trial Radar · NCT07919743

Efficacy of TECAR Therapy in Plantar Fasciitis

Efficacy of Capacitive and Resistive Energy Transfer (TECAR) Therapy in Plantar Fasciitis: A Randomized, Double-Blind, Sham-Controlled Clinical Trial

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Jun 30, 2027

Study completion Aug 30, 2027

Sponsor

Lead sponsor
Ankara Etlik City HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Nov 5, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, sham-controlled clinical trial aims to evaluate the efficacy of Capacitive and Resistive Energy Transfer (TECAR) therapy combined with an exercise program in patients with plantar fasciitis. The effects of active TECAR therapy will be compared with those of sham TECAR therapy, both combined with the same exercise program, in terms of pain intensity, foot function, pressure pain threshold, ultrasonographic plantar fascia thickness, and health-related quality of life. TECAR therapy is a non-invasive physical therapy modality used in musculoskeletal rehabilitation. Although it is increasingly used in clinical practice, evidence from sham-controlled randomized trials in patients with plantar fasciitis remains limited. This study aims to determine whether active TECAR therapy provides additional benefits over sham treatment when combined with exercise. The findings are expected to contribute to the evidence regarding the clinical efficacy of TECAR therapy in the management of plantar fasciitis.

Conditions

  • Plantar Fasciitis

Interventions

  • Capacitive and Resistive Energy Transfer (TECAR) therapyDevice

    Active TECAR therapy will be administered using the BTL TECAR Therapy device for 15 minutes per session, 5 days per week for 2 weeks (10 sessions). Each session will consist of 5 minutes of capacitive mode followed by 10 minutes of resistive mode. Treatment will be applied along the plantar fascia of the symptomatic foot, focusing on the medial calcaneal insertion, using conductive cream and continuous probe movement. The intensity will be adjusted to produce a comfortable, mild thermal sensation without pain.

  • Sham Capacitive and Resistive Energy Transfer (TECAR) TherapyDevice

    Sham TECAR therapy will be administered using the same device, probe, and application procedure as the active treatment for 15 minutes per session, 5 days per week for 2 weeks (10 sessions). The device will not deliver any energy during sham treatment. The application will otherwise be identical to the active treatment procedure.

  • Standardized Exercise ProgramOther

    All participants will receive a standardized exercise program consisting of plantar fascia stretching, gastrocnemius and soleus stretching, and intrinsic foot muscle strengthening (short-foot exercises). Exercises will be performed three times daily. Stretching exercises will consist of 10 repetitions held for 10-15 seconds, while strengthening exercises will consist of 10-15 repetitions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Morning First-Step Pain (VAS)Time frame: Baseline (pre-treatment), 2 weeks (end of treatment), and 6 weeks after treatment completion.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Etlik City Hospital

    Ankara, Yenimahalle, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.